Uncategorized

Enveda’s exercise-simulating obesity tablet clears early clinical test

Published

on

Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version